The HemOnc Pulse
Drs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk
Feb 8, 2024
Discussion on the risks of secondary malignancies from CAR-T therapy, challenges of attributing lymphomas to CAR-T, exploration of insertional mutagenesis impact, concerns about myeloid neoplasms, and unique aspects of filter cell CAR-T therapy.
40:56
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- CAR-T therapy can lead to secondary myeloid neoplasms, emphasizing the need for risk evaluation and patient counseling.
- Variations in CAR constructs may impact rates of secondary malignancies, highlighting the importance of understanding their implications.
Deep dives
Discussion on Secondary Malignancies from CAR-T Cellular Therapy
The podcast episode delves into the topic of secondary malignancies arising from CAR-T cellular therapy. Researchers discuss their findings related to T-cell lymphomas and therapy-related myeloid malignancies post-CAR-T treatment. Dr. Spiegel and Dr. Dahia provide insights into the associations between CAR-T therapy and secondary malignancies. Their studies reported cases of secondary myeloid neoplasms in patients treated with CAR-T, shedding light on the complexities of the risks involved.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
